Heather Theresa Stephenson

US Patent:

20210107981, Apr 15, 2021

Filed:

Oct 12, 2020

Appl. No.:

17/068477

Inventors:

- South San Francisco CA, US
Ryan STAFFORD - Emeryville CA, US
Aaron SATO - Burlingame CA, US
John LEE - San Francisco CA, US
Avinash GILL - Emeryville CA, US
Junhao YANG - Palo Alto CA, US
Heather STEPHENSON - San Jose CA, US

International Classification:

C07K 16/28
A61P 37/00
A61P 35/00

Abstract:

Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

US Patent:

20200377592, Dec 3, 2020

Filed:

May 6, 2020

Appl. No.:

16/867924

Inventors:

- Foster City CA, US
Joshua Goldsmith - San Francisco CA, US
George Kukolj - Mount Royal, CA
Craig S. Pace - Pacifica CA, US
Doug Rehder - Bonsall CA, US
Derek Dean Sloan - Belmont CA, US
Heather Theresa Stephenson - San Jose CA, US
Nathan D. Thomsen - Castro Valley CA, US

International Classification:

C07K 16/28
A61K 47/68
A61K 51/10
A61P 31/18
C07K 16/10

Abstract:

Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.

US Patent:

20200223907, Jul 16, 2020

Filed:

Jul 2, 2019

Appl. No.:

16/460094

Inventors:

- Foster City CA, US
Brian A. Carr - Foster City CA, US
Magdeleine S. Hung - Mountain View CA, US
Manu Kanwar - San Marcos CA, US
Craig S. Pace - Belmont CA, US
Doug Rehder - Bonsall CA, US
Matthew Robert Schenauer - Dana Point CA, US
Loredana Serafini - Orinda CA, US
Heather Theresa Stephenson - San Jose CA, US
Nathan D. Thomsen - Castro Valley CA, US
Helen Yu - Mountain View CA, US
Xue Zhang - San Diego CA, US

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C07K 16/10
A61P 31/18

Abstract:

Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.

US Patent:

20200062807, Feb 27, 2020

Filed:

Sep 6, 2019

Appl. No.:

16/562837

Inventors:

- South San Francisco CA, US
Christopher J. Murray - Soquel CA, US
Junhao Yang - Palo Alto CA, US
Heather Stephenson - San Jose CA, US

International Classification:

C07K 14/245
C07K 16/00
C12P 21/02
C07K 16/06
C07K 16/32
C12N 9/52
C12P 21/00
C12Q 1/686
C12Q 1/689
G01N 30/02
G01N 30/06

Abstract:

The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.

US Patent:

20190233512, Aug 1, 2019

Filed:

Oct 11, 2017

Appl. No.:

16/341015

Inventors:

- South San Francisco CA, US
Alice YAM - Tiburon CA, US
Xiaofan LI - Fremont CA, US
Robert HENNINGSON - Redwood City CA, US
Sihong ZHOU - Foster City CA, US
Heather STEPHENSON - San Jose CA, US
Junhao YANG - Palo Alto CA, US
Aaron SATO - Burlingame CA, US

International Classification:

C07K 16/28
A61K 49/00
A61P 35/00
A61K 51/10

Abstract:

The present disclosure relates to antibodies that selectively bind to folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

US Patent:

20180371086, Dec 27, 2018

Filed:

Jun 21, 2018

Appl. No.:

16/014153

Inventors:

- Foster City CA, US
Joshua Goldsmith - San Francisco CA, US
Craig S. Pace - Belmont CA, US
Derek Sloan - Belmont CA, US
Heather Stephenson - San Jose CA, US
Nathan D. Thomsen - Castro Valley CA, US
George Kukolj - Cambridge MA, US
Doug Rehder - Bonsall CA, US

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C07K 16/28
C07K 16/10
A61K 47/68
A61K 51/10
A61P 31/18

Abstract:

Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.

US Patent:

20180142022, May 24, 2018

Filed:

Nov 10, 2015

Appl. No.:

15/525943

Inventors:

- South San Francisco CA, US
Ryan STAFFORD - Emeryville CA, US
Aaron SATO - Burlingame CA, US
John LEE - South San Francisco CA, US
Avinash GILL - Emeryville CA, US
Junhao YANG - Palo Alto CA, US
Heather STEPHENSON - San Jose CA, US

Assignee:

SUTRO BIOPHARMA, INC. - South san Francisco CA

International Classification:

C07K 16/28
A61P 35/00
A61P 37/00

Abstract:

Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

US Patent:

20170283469, Oct 5, 2017

Filed:

Apr 10, 2017

Appl. No.:

15/483766

Inventors:

- South San Francisco CA, US
Christopher J. MURRAY - Soquel CA, US
Junhao YANG - Palo Alto CA, US
Heather STEPHENSON - San Jose CA, US

International Classification:

C07K 14/245
G01N 30/06
C12Q 1/68
G01N 30/02
C07K 16/06
C12N 9/52

Abstract:

The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.